SLXN Silexion Therapeutics Corp

Nasdaq silexion.com


$ 3.83 $ 0.00 (0 %)    

Friday, 17-Oct-2025 05:07:34 EDT
QQQ $ 592.91 $ 0.00 (0 %)
DIA $ 456.36 $ 0.00 (0 %)
SPY $ 654.30 $ 0.00 (0 %)
TLT $ 91.50 $ 0.00 (0 %)
GLD $ 399.12 $ 0.00 (0 %)
$ 3.56
$ 3.75
$ 3.43 x 157
$ 3.87 x 3
-- - --
$ 3.25 - $ 63.45
58,059
na
2.06M
$ 3.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-29-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, ...

Core News & Articles

- SEC Filing

 silexion-therapeutics-shares-surge-on-positive-preclinical-pancreatic-cancer-data

Silexion's SIL204 showed strong anti-tumor effects in preclinical tests, reaching major metastasis sites in pancreatic canc...

Core News & Articles

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech ...

Core News & Articles

SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Tra...

Core News & Articles

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tu...

Core News & Articles

Silexion Therapeutics Corp. (NASDAQ:SLXN), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies ...

Core News & Articles

Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL20...

Core News & Articles

Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(4.32) per share which missed the analyst consensus estimate ...

Core News & Articles

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purch...

 why-is-silexion-therapeutics-stock-trading-higher-on-thursday

Silexion's SIL204 showed strong KRAS-targeted inhibition across pancreatic, colorectal, and lung cancer cells, supporting i...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION